Research and Markets (http://www.researchandmarkets.com/research/15d57b/united_arab_emirat) has announced the addition of the "United Arab Emirates Pharmaceuticals and Healthcare Report Q3 2008" report to their offering.
The UAE has once again been judged the most attractive market in the Middle East and Africa (MEA) region, retaining its pole position in BMI’s latest Business Environment Ranking table. While not being the largest in size, the market offers plenty of opportunities for growth. Key draws include increasing public and private wealth fuelled by the oil boom, strong and strengthening healthcare infrastructure, approvals of more medicines, a friendly regulatory environment, the absence of significant local competitors, establishment of comprehensive health insurance and the formation of a common market of the six Gulf Co-operation Council (GCC) states.
The above factors have clearly been recognised by foreign companies, with the world’s largest pharmaceutical manufacturer, Pfizer, being the latest corporation to choose the UAE as its new regional medical and marketing headquarters, following the footsteps of US-based biotechnology giants Amgen and Genzyme. Similarly, in January 2007, Dabur International, a wholly-owned subsidiary of Dabur India, indicated its intention to create a manufacturing facility in the UAE, which will originally produce personal care products for the West Asian region. Finally, in February 2008, India's Intas Biopharmaceuticals (IBPL) stated its intention to initially planning to launch three products to treat certain cancers and their side effects, penetrating the single GCC common market. The rising regional demand for medicine is also benefitting local players. The UAE's Globalpharma is beginning to live up to its name following the announcement that it has won good manufacturing practice (GMP) certification from South Africa's Medicines Control Council (MCC), which brings the company a step closer to achieving the approval by the US and the European Union (EU) authorities. In the meantime, the UAE’s changing insurance landscape continues to pose challenges for pharmaceutical manufacturers. While the roll-out of compulsory private insurance for expatriate workers promises to increase the consumption of medicines, foreign insurance companies operating in the Middle East may find their market is limited to kafirs (unbelievers), if they fail to adapt their products to be compliant with the beliefs of Islam. Nevertheless, private insurers continue to look for a foothold in the UAE health insurance market, with Goodhealth Worldwide becoming the latest company to register in the country.
In the public insurance sector, the introduction of new insurance programmes by Abu Dhabi and Dubai, the two largest emirates within the UAE, threatens to limit the private health insurance market to expatriates, as the authorities provide free coverage for all citizens. BMI is also concerned that the five smaller emirates in the UAE are feeling increasingly left behind by the growing autonomy of Dubai and Abu Dhabi.
Key Topics Covered:
- Executive Summary
- United Arab Emirates Pharmaceuticals And Healthcare Industry SWOT
- United Arab Emirates Political SWOT
- United Arab Emirates Economic SWOT
- United Arab Emirates Business Environment SWOT
- Pharmaceutical Business Environment Ratings
- Table: Middle East And Africa Pharmaceutical Business Environment Ratings
- Limits To Potential Returns
- Risks To Realisation Of Returns
- Market Summary
- Regulatory Environment
- Recent Regulatory Developments
- Pharmaceutical Advertising
- Intellectual Property Regime
- Counterfeit Medicines
- Pricing And Reimbursement Regime
- Table: Profit Margins For Medicines In The UAE
- Price Cuts
- Recent Pricing And Reimbursement Developments
- Regional Harmonisation
- Industry Trends And Developments
- Epidemiology
- Healthcare Sector
- Recent Healthcare Sector Developments
- Health Insurance
- Expatriate Worker Insurance
- Table: National Health Insurance Company – Available
- Health Tourism
- International Healthcare Collaboration
- Prescribing Practices
- Domestic Pharmaceutical Sector
- Foreign Companies
- Company Developments
- Pharmaceutical Distribution and Retail
- Recent Developments in Pharmaceutical Distribution and Retail
- Research And Development
- DuBiotech
- Table: Incentives For Companies To Move To DuBiotech
- Complementary and Traditional Medicine
- Medical Devices
- Table: The UAE’s Medical Device Market, 2006-2012 (US$bn unless otherwise stated)
- Recent Developments In The Medical Devices Market
- Industry Forecast Scenario
- Overall Market Forecast
- Table: Drug Expenditure And Prescription Market Indicators, 2006-2012 (AEDmn unless otherwise stated)
- Key Growth Factors – Industry
- Key Growth Factors – Industry
- Table: Health Expenditure Trends, 2006-2012
- Macroeconomic Scenario
- Macroeconomic Scenario
- Table: United Arab Emirates – Economic Activity
- Patented Market Forecasts
- Table: Patented Drug Market Trends, 2006-2012 (US$mn unless otherwise stated)
- Generics Market Forecast
- Table: Generics And Patented Drug Market Indicators, 2006-2012
- OTC Market Forecast
- Table: OTC Drug Market Trends (AEDmn unless otherwise stated)
- Imports/Exports Forecasts
- Table: Pharmaceutical Import/Export Trends (US$mn)
- Other Healthcare Forecasts
- Table: Other Healthcare Data, 2006-2012
- Key Risks To BMI’s Forecast Scenario
- Competitive Landscape
- Table: Key Players In The UAE's Pharmaceutical Market, 2007
- Company Profiles
- Leading Foreign Companies
- GlaxoSmithKline
- Pfizer
- Novartis
- Johnson & Johnson (J&J)
- Sanofi-Aventis
- Abbott Laboratories
- Merck & Co
- Indigenous Manufacturers
- Gulf Pharmaceutical Industries (Julphar)
- Globalpharma
- Modern Pharmaceutical Company (MPC)
- NeoPharma
- BMI Forecast Modelling
- How We Generate Our Pharmaceutical Industry Forecasts
- Pharmaceutical Business Environment Ratings Methodology
- Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
- Weighting
- Table: Weighting Of Components
- Sources
Companies Mentioned:
-GlaxoSmithKline
-Pfizer
-Novartis
-Johnson & Johnson (J&J)
-Sanofi-Aventis
-Abbott Laboratories
-Merck & Co
-Gulf Pharmaceutical Industries (Julphar)
-Globalpharma
-Modern Pharmaceutical Company (MPC)
-NeoPharma
For more information visit http://www.researchandmarkets.com/research/15d57b/united_arab_emirat
Contacts:
Laura Wood
Senior Manager
press@researchandmarkets.com
Fax
from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716
